Barrington Research Estimates DENTSPLY SIRONA Q4 Earnings

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Research analysts at Barrington Research dropped their Q4 2025 EPS estimates for shares of DENTSPLY SIRONA in a report issued on Monday, November 10th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings per share of $0.27 for the quarter, down from their prior estimate of $0.44. Barrington Research currently has a “Outperform” rating and a $14.00 target price on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.36 EPS, FY2026 earnings at $1.40 EPS and FY2027 earnings at $1.62 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.08). The firm had revenue of $904.00 million during the quarter, compared to analysts’ expectations of $900.33 million. DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.50 earnings per share. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS.

Several other brokerages also recently issued reports on XRAY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, October 8th. Evercore ISI dropped their price objective on shares of DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th. UBS Group reduced their target price on DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Friday, September 26th. Finally, Mizuho set a $13.00 price target on DENTSPLY SIRONA in a research report on Friday, November 7th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $16.08.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY opened at $10.84 on Wednesday. The company has a current ratio of 1.69, a quick ratio of 1.11 and a debt-to-equity ratio of 1.13. The company’s 50-day moving average price is $12.79 and its 200 day moving average price is $14.43. DENTSPLY SIRONA has a 52 week low of $10.69 and a 52 week high of $20.59. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -2.29, a PEG ratio of 0.81 and a beta of 1.00.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors have recently made changes to their positions in the stock. Gabelli Funds LLC increased its holdings in shares of DENTSPLY SIRONA by 5.9% during the 3rd quarter. Gabelli Funds LLC now owns 48,608 shares of the medical instruments supplier’s stock worth $617,000 after buying an additional 2,700 shares during the last quarter. Gamco Investors INC. ET AL grew its position in DENTSPLY SIRONA by 38.5% during the third quarter. Gamco Investors INC. ET AL now owns 158,803 shares of the medical instruments supplier’s stock valued at $2,015,000 after acquiring an additional 44,110 shares during the period. Truepoint Inc. acquired a new stake in DENTSPLY SIRONA during the third quarter worth about $1,396,000. Barclays PLC increased its stake in DENTSPLY SIRONA by 50.1% during the third quarter. Barclays PLC now owns 248,273 shares of the medical instruments supplier’s stock worth $3,151,000 after acquiring an additional 82,864 shares during the last quarter. Finally, ARK Investment Management LLC raised its holdings in shares of DENTSPLY SIRONA by 6.4% in the 3rd quarter. ARK Investment Management LLC now owns 226,543 shares of the medical instruments supplier’s stock worth $2,875,000 after purchasing an additional 13,584 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.